Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Exel Composites Plc publishes its January – September Business Review 2017 on 25 October 2017

EXEL COMPOSITES PLC               INVESTOR NEWS               18 OCTOBER 2017 at 11:00 EETExel Composites Plc publishes its January – September Business Review 2017 on Wednesday 25 October 2017 at 9:00 EET. A financial results briefing for investors, analysts and journalists will be held the same day at 12:30 EET at Scandic Hotel Simonkenttä’s Roba meeting room (address Simonkatu 9, Helsinki, Finland). The briefing will be hosted by Riku Kytömäki, President and CEO. Vantaa, 18 October 2017  Exel Composites Plc Riku KytömäkiPresident and CEO

Invitation to ÅF’s Capital Markets Day on November 8, 2017

ÅF invites analysts, investors and media to join the ÅF management for a Capital Markets Day at the ÅF headquarters in Solna-Stockholm on November 8 between 9.00 am and 2.00 pm.During the course of the day we will present ÅF’s new strategy and the journey ahead together with insights into focus areas. The presentation will be in English. The agenda will be presented one week before the Capital Markets Day at www.afconsult.com/capitalmarketsday. To confirm your attendance please register here 

Photocure ASA: FDA grants priority review for Cysview® supplemental New Drug Application (sNDA)

Oslo, Norway, October 18, Photocure ASA (OSE: PHO) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) for Cysview[®] on a priority review basis. With the FDA granting a priority review, a decision is expected in the first half of 2018. The company is looking to expand the label of Cysview to include its use in the outpatient setting to detect the recurrence of bladder cancer using a flexible cystoscope, the detection of carcinoma in situ (CIS) and the repeat administration of Cysview. The filing is a combination drug-

Invitation to conference call and webcast presentation of Metsä Board's interim report for January–September 2017 on 1 November 2017

Metsä Board will publish its interim report for January–September 2017 on Wednesday, 1 November 2017 at 12:00 noon EET. We are pleased to invite you to join conference call and webcast presentation on the same day at 3:00 p.m. EET. Conference call will be held in English.Metsä Board Corporation Investor News 18 October 2017 at 10.15 EET Metsä Board will publish its interim report for January–September 2017 on Wednesday, 1 November 2017 at 12:00 noon EET. We are pleased to invite you to join conference call and webcast presentation on the same day at 3:00 p.m. EET. Conference call will be

ExpreS2ion’s new joint venture, AdaptVac, reaches proof of concept in animals for breakthrough breast cancer vaccine treatment

Hørsholm, Denmark, October 18, 2017 – Today, ExpreS2ion Biotech Holding AB (“ExpreS2ion”) announces that its joint venture, AdaptVac ApS (“AdaptVac”), has reached proof of concept in advanced animal models (POCA) for AV-001, its novel vaccine treatment against breast cancer tumours. This is a significant milestone for AdaptVac in the progress towards clinical development. AdaptVac will now initiate discussions with large pharmaceutical companies regarding a license or collaboration agreement for the clinical development of the project.The scientific results that form the basis of the proof

Sectra’s digital pathology solution selected for external quality assurance program

Linköping, Sweden – October 18, 2017 –  International medical imaging IT and cybersecurity company Sectra  (STO: SECT B) signs digital pathology contract with the Royal College of Pathologists of Australasia Quality Assurance Programs (RCPAQAP). Sectra’s digital pathology solution will be used in training and quality assurance programs for pathology laboratories. It will provide pathologists and scientists with a fast digital pathology solution, available at any time regardless of the participant’s location.“The Sectra solution will enable us to deliver digital

NeuroVive and Lund University Collaboration Receives Grant for Liver Cancer Research

Lund, Sweden, 18 October 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that NeuroVive and Ramin Massoumi at Lund University have been granted 2.5 MSEK from the Swedish Foundation for Strategic Research (SFF) for an Industrial PhD to study the role of cyclophilins in liver cancer. The research will be done within NeuroVive’s project NVP024, which is focused on the development of a novel liver cancer treatment.The overall objective of the research is to develop new therapeutic options for liver cancer by combining

SolunoBC prepares for the future with a new Chairman

SolunoBC strengthens the Board with the appointment of Patrik Sörqvist, who becomes the new Chairman. The company has a strong position and has achieved strong growth on the Swedish UCaaS market (Unified Communications as a Service. Soluno’s ambition is to continue the international expansion. During this expansion, Patrik Sörqvist has the role of broadening the company’s expertise and experience using his network of contacts and his experience of the industry.Patrik Sörqvist has over 20 years international experience of telecoms and cloud services. He was Vice President Cloud for the

Paulig and Fairtrade co-operate in development work in Ethiopia

Paulig’s selection includes several Fairtrade coffees, and during the Fairtrade week starting next Monday, we will introduce the new Reilusti Tumma Mundo coffee. In recent years, our co-operation has also taken new forms, as we have launched a project in Ethiopia that aims to increase the profitability of coffee growing, the quality of coffee crops and the well-being of the entire community. In spring 2016, Paulig and Fairtrade Finland launched a development programme in the Sidama region of Ethiopia to support local coffee growers. The project is also supported by the Ministry for

SpareBank 1 SR-Bank ASA: Presentation of 3rd quarter 2017 accounts

SpareBank 1 SR-Bank’s 3rd quarter accounts will be released at 07.30 am on Wednesday 25 October 2017, and we would like to invite you to a presentation: Time: Wednesday 25 October 2017, 08.15 am Location: SpareBank 1 Markets, Olav V's gate 5 Breakfast is served from 08.00 am. The presentation will be made by CEO Arne Austreid and CFO Inge Reinertsen. This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

Nel ASA: Awarded a contract for approximately mUSD 1.8 and assumes the lead role in the US Government Advanced Water Splitting Benchmarking Project

Proton OnSite (“Proton”), a wholly owned subsidiary of Nel ASA (Nel, OSE: NEL), announced today that it has been awarded a contract for approximately USD 1.8 million for its participation in the US Department of Energy’s (DOE) Advanced Water Splitting Benchmarking Project. Funding for the project will be spread out over its three-year active period. The purpose of this project is to accelerate the cost reduction efforts in generating low-cost hydrogen production from all four major water splitting pathways, including proton exchange membrane (PEM) electrolysis. Proton will take the lead

Insplorion and RISE are granted SEK 350,000 by Vinnova for further miniaturization of the battery sensor

Vinnova has granted SEK 350,000 for the project "Miniaturization of a nanosensor system for batteries" which Insplorion will conduct together with the experts in fiber optics at RISE. The aim of the project is to further develop the design of a fiber-based NPS sensor battery management system, as well as investigate the potential of other applications based on the same platform."This grant allows us to accelerate our own miniaturization work. In addition, we will work closely with RISE and their experts in miniaturization. It's an exciting project that complements our other collaborations

Shamrock Capital signs definitive agreement to become co-owner of BTI Studios through partnership with Altor

Major media and entertainment investors to back globally recognized localization company.The agreement with Shamrock Capital Advisors, LLC (“Shamrock”) comes hot on the heels of the sale of BTI Studios to Altor Fund IV (“Altor”) in July 2017. Shamrock has a rich history of investment in the media and entertainment sector, having been founded in 1978 by the late Roy E. Disney. Shamrock has its roots in LA and holds an impressive portfolio of current investments. BTI Studios is one of the leading localization players globally, providing dubbing, subtitling and access services in over 80

Clavister applies for patent on its advanced traffic management algorithm

With a commitment to accelerated innovation, the company readies solutions for the market with intellectual protections.Clavister (NASDAQ: CLAV), a leader in high-performance network security solutions, has submitted a patent to the Swedish Patent Agency concerning its newly innovated advanced traffic management algorithm, a solution invented by a team of senior software engineers at Clavister. The solution primarily addresses quality of service (QoS) issues in congested networks, a critical challenge in multi-cored systems that need increase performance on every additional CPU core that

INTERIM REPORT JANUARY-SEPTEMBER 2017

Byggmax increased net sales and started the implementation of the new strategy During the third quarter 2017, Byggmax Group increased net sales and started to execute the new strategy launched in June. Netsales increased by 2.5 percent, and profitability measured as EBITDA margin excluding non-recurring items declined by 0.5 percentagepoints. Sales and profitability increased for the Byggmax segment and decreased for Skånska Byggvaror. Implementation ofthe new strategy has started according to plan. The new growth initiatives launched this summer, a Byggmax format for small towns

Mikael Nachemson proposed for election to the Board of Directors of DDM Holding AG

DDM Holding AG (Nasdaq First North: DDM) announces that Mikael Nachemson is proposed to be elected at an Extraordinary General Meeting (“EGM”) as a new member of the Board of Directors of DDM Holding AG. The Board intends to call an EGM in the near future. Mikael Nachemson has solid experience from the finance industry. He has previously been CEO of Bure Equity, AB Custos and E. Öhman J:r AB, and he has also held board positions with a large number of listed and private companies. Mikael Nachemson is currently Chairman of the Board of Påmind AB, a company that he also founded. This is

Management changes at Handelsbanken

Michael Green has been appointed Head of Handelsbanken's operations in Germany from January 1, 2018. He is currently chairman of subsidiaries and foreign regional banks. Upon this change, Michael Green will leave Handelsbanken's Senior Management.The appointment is subject to approval by the authorities.For further information, please contact:Anders Bouvin, President and Group Chief Executive, +46 8–22 92 20Stefan Nilsson, Acting Chief Communications Officer, +46 8–701 89 04, +46 70–225 91 04Johan Wallqvist, Head of Group Media Relations, +46 8–701 80 47, +46 72–206 34 50 This

US FDA ACCEPTS REGULATORY SUBMISSION FOR LYNPARZA IN METASTATIC BREAST CANCER AND GRANTS PRIORITY REVIEW

Lynparza has the potential to offer a new treatment option for patients with germline BRCA-mutated, HER2-negative metastatic breast cancer18 October 2017 07:00 BST Regulatory submission acceptance is first for a PARP inhibitor beyond ovarian cancer AstraZeneca and Merck & Co., Inc., (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCAm), HER2-negative

Q4: Strong sales growth and earnings performance

Fourth quarter · Net sales for the quarter rose 15.9 per cent to SEK 2,262 million (1,952). · Organic growth in fixed exchange rates was 12.2 per cent (10.2). · The gross margin amounted to 14.3 per cent (15.3). · Adjusted EBITA increased to SEK 92 million (81). · EBIT totalled SEK 74 million (65). · Items affecting comparability amounted to a negative SEK 1 million (-). · Profit for the quarter totalled SEK 48 million (25). · Earnings per share before dilution, including discontinued operations, amounted to SEK 0.64 (0.33). Earnings per share after dilution,

High risk of injury in young elite athletes

[PRESS RELEASE 2017-10-18] Every week, an average of three in every ten adolescent elite athletes suffer an injury. Worst affected are young women, and the risk of injury increases with low self-esteem, especially in combination with less sleep and higher training volume and intensity, a doctoral thesis from Karolinska Institutet shows.Even though thousands of young elite athletes participate in organised sporting events every year, knowledge of injury and its consequences is limited. A thesis by Philip von Rosen, researcher at the Department of Neurobiology, Care Sciences and Society, can

NCC to build superstructure over treatment plant in Helsingborg

NCC has been commissioned by Nordvästra Skånes Vatten och Avlopp (NSVA) to construct a superstructure over the treatment plant in central Helsingborg, as well as to build an extension. The work is being carried out to enable an urban regeneration project adjacent to the treatment plant. The order value is expected to amount to approximately SEK 275 million.A new city district will be built next to the Öresundsverket wastewater treatment plant in central Helsingborg. For this to happen, primarily considering the odor, the facility will be built over and partially covered with green spaces.

Read original

Interim report January-September 2017

Quarter 3, 2017  · Incoming orders amounted to SEK 761.0m (696.6), which organically is an increase of 11.6 percent compared with the same period last year. · Net sales amounted to SEK 768.7m (792.0), which organically is a decrease of 0.8 percent compared with the same period last year. · Operating profit was SEK 69.3m (68.6), giving an operating margin of 9.0 percent (8.7). · Net profit was SEK 42.9m (47.9). · Earnings per share were SEK 3.67 (4.09). January - September 2017  · Incoming orders amounted to SEK 2,341.5m (2,161.8), which organically is an increase of

Interim report for 1 January – 30 September 2017

SIGNIFICANTLY IMPROVED OPERATING INCOMETHIRD QUARTER[1] · Net sales increased by 5.5 per cent to SEK 868.1 (822.6) million · The gross margin increased by 5.6 percentage points to 23.6 (18.0) per cent · Operating income before depreciation, amortization and impairment was SEK 22.0 (-1.3) million · Operating income totaled SEK 3.4 (-30.9) million · Basic and diluted earnings per share including discontinued operations improved to SEK -0.01 (-0.31)  · Cash and cash equivalents amounted to SEK 433.8 (180.9) million at the end of the quarter  FIRST NINE MONTHS[1] ·

There are no items matching the current filter
There are no more items matching the current filter
Back to top